Astria Therapeutics (NASDAQ:ATXS) reported quarterly losses of $(0.87) per share. This is a 42.62 percent decrease over losses of $(0.61) per share from the same period last year.
‘Skyrora And Spirit To Enhance Future UK Launch Capability’
https://www.spiritaero.com/pages/release/skyrora-and-spirit-to-enhance-future-uk-launch-capability/ Skyrora and Spirit AeroSystems have announced a collaboration on orbital launch capability. The companies